Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Michael Aboud
Observed names:
Aboud, Michael,
M Aboud,
M. Aboud
Institution:
ViiV Healthcare (United Kingdom)
Observed institutions:
Guy's Hospital,
St Thomas' Hospital,
Janssen (Belgium),
Johns Hopkins University,
Guy's and St Thomas' NHS Foundation Trust,
Barts Health NHS Trust,
Johns Hopkins Medicine,
Royal London Hospital,
ViiV Healthcare (United Kingdom),
GlaxoSmithKline (Brazil)
show all 10
ORCID:
0000-0001-5878-0060
Observed ORCID:
0000-0001-5878-0060
OpenAlex ID:
A5057393643
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials
2018
·
Pedro Cahn
, Juan Sierra Madero
, et al.
·
The Lancet
·
449
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies
2018
·
Josep M Llibre
, Chien-Ching Hung
, et al.
·
The Lancet
·
387
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study
2020
·
Jean van Wyk
, Faïza Ajana
, et al.
·
Clinical Infectious Diseases
·
314
PDF
Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials
2019
·
Pedro Cahn
, Juan Sierra Madero
, et al.
·
JAIDS Journal of Acquired Immune Deficiency Syndromes
·
243
PDF
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis
2021
·
Amy G. Cutrell
, Jonathan M. Schapiro
, et al.
·
AIDS
·
233
Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial
2019
·
Michael Aboud
, Richard Kaplan
, et al.
·
The Lancet Infectious Diseases
·
203
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial
2022
·
Olayemi Osiyemi
, Stéphane De Wit
, et al.
·
Clinical Infectious Diseases
·
161
PDF
Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial
2019
·
Kelly E Dooley
, Richard Kaplan
, et al.
·
Clinical Infectious Diseases
·
136
PDF
Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies
2019
·
Michael Aboud
, Chloe Orkin
, et al.
·
The Lancet HIV
·
135
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study
2017
·
Catherine Orrell
, Debbie P Hagins
, et al.
·
The Lancet HIV
·
134
Dolutegravir/Abacavir/Lamivudine versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study
2016
·
Benoît Trottier
, Jordan E Lake
, et al.
·
Antiviral Therapy
·
117
Psychiatric Symptoms in Patients Receiving Dolutegravir
2016
·
Anna Fettiplace
, Chris Stainsby
, et al.
·
JAIDS Journal of Acquired Immune Deficiency Syndromes
·
115
Insulin resistance and HIV infection: a review
2007
·
M. Aboud
, A. Elgalib
, et al.
·
International Journal of Clinical Practice
·
86
PDF
Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study
2010
·
M. Aboud
, A. Elgalib
, et al.
·
International Journal of Clinical Practice
·
59
PDF
Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health
2017
·
Grace A. McComsey
, Sergio Lupo
, et al.
·
AIDS
·
58
P032: Dolutegravir versus raltegravir in ARV-experienced INI-naïve HIV+ adults: 48-week subgroup analysis of Latin American subjects in the SAILING study
2015
·
Pedro Cahn
, Jaime Andrade-Villanueva
, et al.
·
Journal of the International AIDS Society
·
40
Durable Efficacy of Dolutegravir (DTG) Plus Lamivudine (3TC) in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI Studies
2020
·
P. Cahn
, J. Sierra Madero
, et al.
·
Journal of Infection and Public Health
·
24
The assessment of metabolic syndrome in UK patients with HIV using two different definitions: CREATE 2 study
2010
·
Ali Elgalib
, Michael Aboud
, et al.
·
Current Medical Research and Opinion
·
24
900. Switching to DTG/3TC Fixed-Dose Combination (FDC) Is Non-inferior to Continuing a TAF-Based Regimen (TBR) in Maintaining Virologic Suppression Through 144 Weeks (TANGO Study)
2021
·
Olayemi Osiyemi
, Faïza Ajana
, et al.
·
Open Forum Infectious Diseases
·
19
Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis
2020
·
Joseph Eron
, Chien-Ching Hung
, et al.
·
JAIDS Journal of Acquired Immune Deficiency Syndromes
·
19
Prevalence of Pretreatment and Acquired HIV-1 Mutations Associated with Resistance to Lamivudine or Rilpivirine: A Systematic Review
2018
·
Vani Vannappagari
, Leigh Ragone
, et al.
·
Antiviral Therapy
·
17
Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) Fixed-Dose Combination (FDC) Compared With Ritonavir-Boosted Atazanavir (ATV/r) Plus Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in Treatment-Naive Women With Human Immunodeficiency Virus (HIV)-1 Infection (ARIA Study): Analyses by Race Subgroups
2016
·
Debbie Hagins
, Craig Dietz
, et al.
·
Open Forum Infectious Diseases
·
16
Superior Efficacy of Dolutegravir (DTG) Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Compared with lopinavir/ritonavir (LPV/r) Plus 2 NRTIs in Second-Line Treatment — 48-week Data from the DAWNING Study
2019
·
M. Aboud
, R. Kaplan
, et al.
·
Journal of Infection and Public Health
·
15
PDF
Switching to DTG/3TC fixed-dose combination (FDC) Is non-inferior to continuing a TAF-based regimen in maintaining virologic suppression through 48 weeks (TANGO Study)
2020
·
J. Van Wyk
, F. Ajana
, et al.
·
Journal of Infection and Public Health
·
12
PDF
Psychiatric outcomes observed in patients living with HIV using six common core antiretrovirals in the Observational Pharmaco-Epidemiology Research and Analysis database
2018
·
Ricky Hsu
, Jennifer Fusco
, et al.
·
Therapeutic Advances in Drug Safety
·
12
PDF
Show more works
View as search
Works count:
70
Citation count:
3,109
H-index:
19
I10-index:
27
Year
Topic
Type